Precision BioSciences Stock (NASDAQ: DTIL)

Precision BioSciences (NASDAQ:DTIL) Stock, Quote.Headers.trade-ideas

Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACIC

ADIL

ARVN

BIVI

CRDF

DCFC

DELL

DMTK

DTIL

ESTC

EVBG

GRTS

HLTH

HUMA

JAGX

JAKK

LIFW

MINM

NTAP

NYCB

OPRA

RDNT

REAL

RGNX

RILY

RMBS

ROOT

RPAY

SANA

SCLX

SENS

SIDU

SOUN

TTEC

VANI

VLCN

VTYX

XPOF

YMAB

Shares of  Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Equities

Mid Cap

Guidance

TGTX

TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S. 

Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?

Precision BioSciences, Inc. (NASDAQ: DTIL) shares are trading higher Tuesday after the company announced it has signed a licensing agreement wit

Why Precision BioSciences Stock Is Up Today

Precision BioSciences, Inc. - Common Stock

Precision BioSciences Inc

RAIR Technologies, an open-source platform for building decentralized Web3 applications, has been accepted into the Denarii Labs Accelerator, a competitive program aimed at helping early-stage Web3 companies develop and fine-tune their tokenomics. 
The 12-week accelerator program, led by RedBeard Ventures and supported by advisory firms such as Futureverse, will provide RAIR Technologies with strategic mentorship and guidance as it strengthens its core technology and token models, RAIR Technologies said in a statement to Benzinga.
Denarii Labs is known for offering support in tokenomics and launch strategies for Web3 startups, focusing on aligning business models with token structures that can drive sustainable growth. 
The accelerator's selection process is highly competitive, ensuring that only the most promising companies in the Web3 space are chosen. 
RAIR Technologies will use this opportunity to refine the tokenomics of its RAIRprotocol, a tool designed to enable decentralized application development, asset creation, and royalty tracking.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40989296/ethereum-outshines-bitcoin-after-u-s-federal-reserve-rate-cut-but-heres-how-volatility-cou">Ethereum Outshines Bitcoin After U.S. Federal Reserve Rate Cut, But Here&#8217;s How Volatility Could Crash The Party</a>
"We couldn't be more proud to be accepted into this unique and elite program for the Web3 industry," said Ed Prado, CEO of RAIR Technologies. "Denarii Labs will allow us to drill down on our tokenomics before we significantly expand both the technology and our partner base."
RAIR's acceptance into the program comes at a crucial time, as the company prepares to raise additional funding and explore new partnerships. 
With mentorship from industry leaders such as Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), GSR and Omniscia, along with legal guidance from Fenwick &amp; West, RAIR Technologies will focus on refining its business model and investor readiness.
The company previously participated in Sony's accelerator program, which resulted in a partnership with Soneium, Sony's blockchain initiative.
These topics will be explored in depth at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry experts will discuss the future of Web3, blockchain innovation and tokenomics in the decentralized economy.
Read Next: • <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40985125/bitcoins-on-chain-metrics-are-turning-bullish-what-is-going-on">Bitcoin&#8217;s On-Chain Metrics Are Turning Bullish: What Is Going On?</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

RAIR Technologies Joins Denarii Labs Accelerator To Refine Web3 Tokenomics

Telegram's CEO Pavel Durov agreed to provide user IP addresses and phone numbers to authorities in response to valid <a href="https://www.benzinga.com/topic/law">legal requests</a>.
Following his arrest in France last month, Durov, who previously resisted government demands for user data, changed Telegram's terms of service to prevent criminals from exploiting the app, <a href="https://www.bloomberg.com/news/articles/2024-09-23/telegram-ceo-durov-says-app-to-provide-more-data-to-governments">per</a> Bloomberg's report.
French authorities allege Telegram, with its reputation for protecting privacy and using encryption, has become a hub for criminal activities. 
Durov, a dual French-Russian national, denied these charges, stating the misuse of technology should not be blamed on its creators. He remains prohibited from leaving the country after being released on a $5.5 million bail.
Amid legal troubles, Telegram has announced new measures to combat misuse of the platform. Durov revealed the company began using artificial intelligence and human moderation to filter problematic content from search results.
&#8220;We've already started this process internally,&#8221; he stated, adding that more details will be shared soon.
The European Union has been tightening regulations on encrypted communication, even debating proposals such as client-side or on-device scanning of private messages and photos — measures that Al Jazeera <a href="https://www.aljazeera.com/economy/2024/6/20/orwellian-eus-push-to-mass-scan-private-messages-on-whatsapp-signal">characterized</a> as "Orwelian."
Meredith Whittaker, president of Signal, reflected on such measures earlier this year, <a href="https://signal.org/blog/pdfs/upload-moderation.pdf">stating</a> &#8220;There is no way to implement such proposals without undermining encryption and creating vulnerabilities.&#8221;
Preston Bryne, a senior fellow at the Adam Smith Institute, raised concerns about the broader implications of Durov's case for online censorship.
&#8220;European states are trying to dictate to foreign companies what content they can and cannot host,&#8221; he <a href="https://prestonbyrne.com/2024/08/24/thoughts-on-the-durov-arrest/">noted</a>, likening the situation to selective enforcement targeting political adversaries.
French President Emmanuel Macron dismissed those allegations calling them "a part of an independent investigation," <a href="https://www.lemonde.fr/en/pixels/article/2024/08/28/telegram-ceo-pavel-durov-formally-indicted-prohibited-from-leaving-france_6722943_13.html">per</a> Le Monde.
This decision is certain to impact Telegram's business model, which was rooted in the platform's commitment to protecting users&#8217; privacy. Even before this turnaround, the company's financials were not stellar, as, according to documents obtained <a href="https://www.ft.com/content/242552a9-4280-46c0-9d61-bcf6ccd14400">by</a> the Financial Times, as it lost $259 million in 2023.
It is unclear whether the possible user exodus might benefit competitors like Signal or WhatsApp. Following the news, Meta Platform Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) stock closed at a new all-time high of $573.98
Now Read:  • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40989179/meta-connect-2024-preview-cheaper-vr-expected-analysts-see-augmented-reality-and-ai">Meta Connect 2024 Preview: Cheaper VR Expected, Analysts See Augmented Reality And AI As Major Focus</a>

Photo: Shutterstock

Eurozone

Legal

Global

Tech

Telegram Uses AI To Filter Problematic Data, Will Share User Info To Authorities

STOCK CLOSES NEAR HIGH OF THE DAY
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="810" height="742" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/23200849/Screen-Shot-2024-09-23-at-4.10.37-PM.png" alt="" class="wp-image-1409" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/23200849/Screen-Shot-2024-09-23-at-4.10.37-PM.png 810w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/23200849/Screen-Shot-2024-09-23-at-4.10.37-PM-300x275.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/09/23200849/Screen-Shot-2024-09-23-at-4.10.37-PM-768x704.png 768w" sizes="(max-width: 810px) 100vw, 810px" /></figure>
Today, TradePulse&#8217;s latest Power Inflow alert indicated institutional volume is coming into Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), signaling a shift from net selling to buying. This shift is a key indicator of rising investor confidence and the potential for an uptrend in BKNG&#8217;s stock.
At 10:02 AM ET on September 23rd BKNG registered a Power Inflow at a price of $4062.73. Following this signal, the stock reached its high point at 3:55 EDT, climbing over 40 points ($4104.87) during the day, translating to an approximate increase of 1.0%. This alert is crucial for investors relying on order flow analytics, suggesting the beginning of an uptrend and presenting a valuable opportunity for those anticipating higher prices. Observers are now closely monitoring BKNG for sustained positive momentum, viewing this as a bullish sign.
Understanding Power Inflow:
A Power Inflow is identified by a surge in buy orders over sell orders, typically occurring within the first one or two hours after the market opens. This phenomenon is observed in ten to twenty stocks daily, reflecting the initial strategies and reactions of large institutional investors. Analyzing the size, timing, and price of these transactions helps signal shifts in market sentiment and potential price changes. For those interested in monitoring more stocks exhibiting Power Inflows, visiting the TradePulse website provides comprehensive insights and updates on daily occurrences.
Importance of Power Inflow:
Power Inflows are crucial as they offer early indications of potential uptrends, enabling traders to act even before the market fully adjusts. Such a change is commonly viewed as a sign of larger inflows than retail is capable of producing, indicating institutional interest and a short-term uptrend in the stock. Although not always marking the lowest point, stocks tend to rise following a Power Inflow. This makes these signals especially valuable for identifying strategic entry points and planning short-term investments, as they provide an opportunity to capitalize on upward momentum ahead of wider market recognition.
Strategic Actions Following a Power Inflow:
After detecting a Power Inflow, traders should view it as a potential entry buying point but also confirm the trend with TradePulse's additional indicators such as Momentum, Daily, and Large Deal flows to ensure its strength and viability. Prompt action, combined with strategic stop-loss settings, can maximize returns and minimize risks. This comprehensive approach allows traders to make more informed decisions, optimizing their trading strategies in alignment with real-time market dynamics.
If you want to stay updated on the latest options trades for Booking Holdings Inc.,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trade alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like<a href="https://finitusa.com/en/"> Finit USA</a>, responsible for parts of the data within this article. 
After Market Close UPDATE:
The price at the time of the Power Inflow was $4062.73. The returns on the High price ($4104.87) and Close price ($4097.08) after the Power Inflow were respectively 1.0% and 0.8%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

BKNG

Tradepulse Power Inflow Alert: Booking Holdings Inc. Climbs Over 40 Points After Signal

O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) has outperformed the market over the past 15 years by 13.85% on an annualized basis producing an average annual return of 25.72%. Currently, O'Reilly Automotive has a market capitalization of $64.99 billion. 
Buying $1000 In ORLY: If an investor had bought $1000 of ORLY stock 15 years ago, it would be worth $30,563.32 today based on a price of $1119.84 for ORLY at the time of writing.
<h3>O'Reilly Automotive's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727127024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLY

$1000 Invested In This Stock 15 Years Ago Would Be Worth $31,000 Today

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 20 years by 8.05% on an annualized basis producing an average annual return of 16.54%. Currently, Adobe has a market capitalization of $234.06 billion. 
Buying $100 In ADBE: If an investor had bought $100 of ADBE stock 20 years ago, it would be worth $2,125.94 today based on a price of $527.87 for ADBE at the time of writing.
<h3>Adobe's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727127019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

$100 Invested In This Stock 20 Years Ago Would Be Worth $2,100 Today

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares moved higher Monday as investors anticipate the company's third-quarter delivery figures and <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40987087/us-stocks-stall-gold-updates-record-highs-tesla-rallies-whats-driving-markets-monday">the release of its robotaxi.&nbsp;</a>
The Details: Tesla shares climbed nearly 5% Monday after Barclays analyst Daniel Levy said he expects Tesla deliveries to come in higher than the consensus estimate of 460,000, according to <a href="https://finance.yahoo.com/news/tesla-stock-pops-amid-bullish-sales-forecast-as-robotaxi-unveiling-looms-181255883.html?utm_campaign=bm&amp;utm_medium=newsletter&amp;utm_source=morning_brew">a report</a> from Yahoo Finance.&nbsp;
The Barclays analyst expects Tesla to deliver about 470,000 EVs for the quarter due to an uptick in sales in China.&nbsp;
"Given the positive data points reported thus far in the quarter, particularly in China, we believe Tesla&#8217;s sales trajectory is well understood and investors are expecting a stronger result," Levy wrote.
Read Next: <a href="https://www.benzinga.com/news/earnings/24/09/40948948/homebuilder-lennar-reports-better-than-expected-q3-results-details">Homebuilder Lennar Reports Better-Than-Expected Q3 Results: Details</a>
Levy also expects Tesla's long-awaited "Robotaxi Day" scheduled for Oct. 10 to boost the stock. Tesla CEO Elon Musk has<a href="https://www.benzinga.com/news/24/07/39929718/tesla-robotaxi-unveiling-set-for-oct-10-here-are-the-updates-from-company-ceo-elon-musk-on-its-upcom"> hinted at the possibility</a> of the first unsupervised Tesla robotaxi ride by the end of 2024.
"It's difficult, obviously, my predictions on this have been overly optimistic in the past," Musk said. "…based on the current trend… you could do [it] unsupervised possibly by the end of this year. I would be shocked if we cannot do it next year."
<h1 class="wp-block-heading">TSLA Stock Prediction 2024</h1>
Tesla&#8217;s revenue growth in FY23 was 18.8%, reflecting the influence of various factors including the macroeconomic environment, demand for its products and services, and its position relative to competitors. This growth is a critical indicator for investors assessing the company&#8217;s future prospects.
Some macro factors that could impact the company's performance in the next year include higher interest rates, progress on reeling in inflation and labor market strength. The Fed's benchmark rate is currently at 4.83%, while PPI recently came in at 0.2%, growing 1.7% from last year. The unemployment rate was most recently reported as 4.2%.
An investor should pay attention to economic conditions to decide whether they think the macro environment is positive or negative for Tesla stock. For real-time economic data and breaking market updates, <a href="https://pro.benzinga.com/">check out Benzinga Pro. Try it for free.</a>
How does this stack up against Tesla's peers? Investors may also want to analyze a stock in comparison to companies with similar products or in similar industries. 
Tesla operates in the Consumer Discretionary sector. The stock has experienced an average annual growth of -1.06% compared to the -37.76% average of its peer companies. This is below the broader sector movement of Tesla.
TSLA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Tesla shares ended Monday's session 1.22% higher at $250.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40957779/shipping-giants-fedex-ups-stocks-slip-friday-whats-going-on">Shipping Giants FedEx, UPS Stocks Slip Friday: What&#8217;s Going On?</a></li>
</ul>
Photo: Courtesy of Tesla, Inc.

TSLA

What Happened With Tesla Stock Today?

HEI intends to use the net proceeds from the offering to fund its contribution to the expected Maui wildfire tort litigation settlement and for general corporate purposes.

Offerings

Hawaiian Electric Industries Intends To Make Offering Of $500M Of Shares Of Its Common Stock

SSIC

Silver Spike Investment Says Stockholders Have Voted At Special Meeting Of Stockholders To Approve Proposal Related To Acquisition Of CALP Loan Portfolio

N-Sorb leverages company&#39;s proven 3-Phase Activ-Polymer&nbsp;platform technology to address recent concerns related to N-nitrosamine impurities in pharmaceuticals.

AptarGroup Says N-Sorb Nitrosamine Mitigation Solution Has Been Accepted Into FDA Emerging Technology Program

Ratings for Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.43, with a high estimate of $31.00 and a low estimate of $17.00. Highlighting a 18.08% decrease, the current average has fallen from the previous average price target of $28.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1727125287_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Grocery Outlet Holding among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Anthony Bonadio</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Grocery Outlet Holding. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Grocery Outlet Holding compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Grocery Outlet Holding's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Grocery Outlet Holding's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Grocery Outlet Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Grocery Outlet Holding</h2>
Grocery Outlet Holding Corp is a grocery store operator in the United States. Its flexible buying model allows them to offer quality, name-brand opportunistic products at prices generally 40% to 70% below those of conventional retailers. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
<h3>Financial Insights: Grocery Outlet Holding</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Grocery Outlet Holding's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.71% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Grocery Outlet Holding's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.24% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Grocery Outlet Holding's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.46%, the company showcases effective utilization of assets.
Debt Management: Grocery Outlet Holding's debt-to-equity ratio is below the industry average at 1.25, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

7 Analysts Assess Grocery Outlet Holding: What You Need To Know

13 analysts have expressed a variety of opinions on Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $96.92, a high estimate of $115.00, and a low estimate of $80.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.33%. 
<img src="https://www.benzinga.com/files/images/story/2024/1727125260_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Microchip Technology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$103.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Microchip Technology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Microchip Technology compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Microchip Technology's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Microchip Technology's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MCHP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Microchip Technology analyst ratings.</a>
<h2>About Microchip Technology</h2>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
<h3>Microchip Technology: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Microchip Technology's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -45.76% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Microchip Technology's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 10.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Microchip Technology's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.98%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Microchip Technology's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.82%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Microchip Technology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.97, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MCHP

13 Analysts Assess Microchip Technology: What You Need To Know

Throughout the last three months, 4 analysts have evaluated Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.0, with a high estimate of $67.00 and a low estimate of $59.00. This upward trend is apparent, with the current average reflecting a 14.96% increase from the previous average price target of $55.67.
<img src="https://www.benzinga.com/files/images/story/2024/1727125251_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Jefferies Financial Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jefferies Financial Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jefferies Financial Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Jefferies Financial Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Jefferies Financial Gr's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JEF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jefferies Financial Gr analyst ratings.</a>
<h2>Discovering Jefferies Financial Gr: A Closer Look</h2>
Jefferies Financial Group Inc is a diversified financial services company. It has two reportable segments; Investment Banking and Capital Markets which is also the majority revenue generating segment, includes securities, commodities, corporate lending, futures and foreign exchange capital markets activities and its investment banking business, which provides underwriting and financial advisory services to clients across different sectors. The Asset Management reportable business segment provides alternative investment management services to investors in the U.S. and overseas and generates investment income from capital invested in and managed by it or its affiliated asset managers.
<h3>Financial Milestones: Jefferies Financial Gr's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Jefferies Financial Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 52.39% as of 31 May, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.75%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Jefferies Financial Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.47%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Jefferies Financial Gr's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.23%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Jefferies Financial Gr's debt-to-equity ratio is below the industry average at 2.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 4 Analyst Ratings For Jefferies Financial Gr

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 15 years by 6.54% on an annualized basis producing an average annual return of 18.4%. Currently, RBC Bearings has a market capitalization of $8.67 billion. 
Buying $1000 In RBC: If an investor had bought $1000 of RBC stock 15 years ago, it would be worth $12,698.64 today based on a price of $297.91 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727125215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning RBC Bearings Stock In The Last 15 Years

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 10 years by 6.67% on an annualized basis producing an average annual return of 17.87%. Currently, Icon has a market capitalization of $24.54 billion. 
Buying $100 In ICLR: If an investor had bought $100 of ICLR stock 10 years ago, it would be worth $515.21 today based on a price of $296.30 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727125210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICLR

Here's How Much $100 Invested In Icon 10 Years Ago Would Be Worth Today

During the last three months, 24 analysts shared their evaluations of Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $88.42, along with a high estimate of $98.00 and a low estimate of $75.00. Marking an increase of 1.85%, the current average surpasses the previous average price target of $86.81. 
<img src="https://www.benzinga.com/files/images/story/2024/1727125208_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Uber Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Conor Cunningham</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Uber Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Uber Technologies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Uber Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UBER/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Uber Technologies analyst ratings.</a>
<h2>Get to Know Uber Technologies Better</h2>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides "aerial ride-sharing." Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 150 million users who order rides or food at least once a month.
<h3>Uber Technologies: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Uber Technologies showcased positive performance, achieving a revenue growth rate of 15.93% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.67%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Uber Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Uber Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

Navigating 24 Analyst Ratings For Uber Technologies

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares are rising in extended trading Monday after the company announced the completion of its <a href="https://www.benzinga.com/pressreleases/24/09/g40990738/gamestop-completes-at-the-market-equity-offering-program">at-the-market offering program</a>.
What Happened: After the market close on Monday, GameStop said it completed its <a href="https://www.benzinga.com/news/earnings/24/09/40803991/gamestop-q2-earnings-highlights-revenue-miss-eps-beat-cash-update-and-more">previously announced</a> offering program. 
On Sept. 10, GameStop updated its prospectus to allow the company to offer and sell up to 20 million shares of its common stock from time to time. 
The video game retailer announced Monday it sold the maximum number of shares registered under the program for gross proceeds of approximately $400 million. GameStop expects to use net proceeds for general corporate purposes, which may include acquisitions and investments.
GameStop stock is extremely popular among retail investors, which has helped spark some wild swings in the stock in recent years. GameStop management has taken advantage of the volatility by raising cash several times along the way. 
GameStop had $4.204 billion in cash, cash equivalents and marketable securities as of the end of the second quarter. 
Don&#8217;t Miss: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40971260/trumps-historic-bitcoin-transaction-ethereum-co-founder-backs-trump-over-harris-for-crypto">Trump&#8217;s Historic Bitcoin Transaction, Ethereum Co-Founder Backs Trump Over Harris For Crypto, Gamestop Customer&#8217;s Bitcoin Windfall, And More: This Week In Cryptocurrency</a>
GME Price Action: GameStop shares were up 1.34% in after-hours, trading at $22.31 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.flickr.com/photos/jjbers/">JJBers</a> from Flickr.

GameStop Stock Jumps Monday After The Bell: What's Going On?

EARN

Ellington Credit Postpones Its 2024 Annual Meeting Of Shareholders, Originally Scheduled For September 26, 2024

Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) shares are trading lower in Monday's after-hours session after the company announced a $2 billion private placement of <a href="https://www.benzinga.com/pressreleases/24/09/b40990749/snowflake-announces-proposed-private-placement-of-2-0-billion-of-convertible-senior-notes">senior convertible notes.</a>
The Details: Snowflake announced it intends to offer $1 billion aggregate principal amount of its convertible senior notes due 2027 and a $1 billion aggregate principal amount of its convertible senior notes due 2029.
The company also intends to grant the initial purchasers of the notes options to purchase up to an additional $150 million aggregate principal amount of the 2027 notes and up to an additional $150 million aggregate principal amount of the 2029 notes.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/09/40948948/homebuilder-lennar-reports-better-than-expected-q3-results-details">Homebuilder Lennar Reports Better-Than-Expected Q3 Results: Details</a>
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Snowflake shares are trading below the stock&#8217;s 50-day moving average of $121.30 and near its 52-week low of $107.13.&nbsp;
<h1 class="wp-block-heading">Will SNOW Stock Go Up?</h1>
When trying to assess whether or not Snowflake will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $166.93 on Snowflake. The Street high target is currently at $220 and the Street low target is $121. Of all the analysts covering Snowflake, 19 have positive ratings, nine have neutral ratings and no one has negative ratings.
In the last month, no analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Snowflake have performed in recent history. 
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Snowflake is 40.11% down year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Snowflake, visit <a href="https://www.benzinga.com/quote/SNOW">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
SNOW Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Snowflake shares are down 2.62% after-hours at $110.29 at the time of publication Monday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40957779/shipping-giants-fedex-ups-stocks-slip-friday-whats-going-on">Shipping Giants FedEx, UPS Stocks Slip Friday: What&#8217;s Going On?</a></li>
</ul>
Image: Shutterstock&nbsp;

After-Hours Center

SNOW

Snowflake Stock Dips On Offering After-Hours: What To Know

The Notes were priced at&nbsp;98.855%&nbsp;of the principal amount and will mature on February 1, 2035. The offering is expected to close on September 26, 2024, subject to the satisfaction of customary closing conditions. The Notes will be fully and unconditionally guaranteed, jointly and severally, by the Company, Invitation Homes OP GP LLC, and IH Merger Sub, LLC.

INVH

Invitation Homes Prices Public Offering Of $500M Of 4.875% Senior Notes Due 2035

Financial giants have made a conspicuous bullish move on Vistra. Our analysis of options history for Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) revealed 96 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $643,223, and 84 were calls, valued at $7,549,105.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $155.0 for Vistra during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Vistra's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vistra's whale activity within a strike price range from $50.0 to $155.0 in the last 30 days. 
<h3>Vistra Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727124345_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$24.4</td>
<td>$23.9</td>
<td>$24.2</td>
<td>$90.00</td>
<td>$605.0K</td>
<td>802</td>
<td style="text-align: right;">253</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$34.5</td>
<td>$34.2</td>
<td>$34.5</td>
<td>$115.00</td>
<td>$345.0K</td>
<td>0</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$21.6</td>
<td>$21.3</td>
<td>$21.3</td>
<td>$87.50</td>
<td>$223.6K</td>
<td>708</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.2</td>
<td>$10.1</td>
<td>$10.1</td>
<td>$120.00</td>
<td>$135.3K</td>
<td>3.1K</td>
<td style="text-align: right;">193</td>
</tr>
<tr>
<td>VST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.7</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$85.00</td>
<td>$112.6K</td>
<td>162</td>
<td style="text-align: right;">176</td>
</tr>
</tbody>
</table>

<h3>About Vistra</h3>
Vistra Energy is one of the largest power producers and retail energy providers in the us Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, and solar power generation along with one of the largest utility-scale battery projects in the world. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.
Having examined the options trading patterns of Vistra, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Vistra</h3>
<ul>
<li>Currently trading with a volume of 15,603,256, the VST's price is up by 3.85%, now at $112.03. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About Vistra</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $118.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Vistra, targeting a price of $132. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Vistra, maintaining a target price of $125. 
&#x2A; In a cautious move, an analyst from Jefferies downgraded its rating to Buy, setting a price target of $99. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vistra with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Market Whales and Their Recent Bets on VST Options

Notable earnings before Thursday's open

Precision BioSciences Q2 2024 Earnings Preview

Precision BioSciences GAAP EPS of $4.70 beats by $6.32, revenue of $49.9M beats by $41.58M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
With the market struggling amid rising recession fears, now may be the ideal time to consider <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. First, the sector itself is a financially lucrative one. Last year, the ecosystem <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion</a>. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion.



Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for solutions that address the human condition. From cancer to autoimmune diseases and other conditions and ailments, the search for effective treatments is a perpetual one. Not only that, a healthy society is an economically productive and efficient one.



Therefore, it&rsquo;s no surprise that government support and incentives underline various biotech-related initiatives. It&rsquo;s in all of our best interests to promote overall wellness. And in that sense, the narrative is recession resistant. With that in mind, below are biotech stocks you can now pick up on a relative discount.



<h2>Crispr Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/crispr_crsp1600-300x169.jpg" alt="CRISPR (CRSP) logo within a DNA sequence"><div>Source: Catalin Rusnac/ShutterStock.com</div></div>One of the most groundbreaking innovators among biotech stocks, Crispr Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/">CRSP</a>) specializes in gene-editing therapies. Primarily, the company&rsquo;s CRISPR/Cas9 platform &ndash; a genome-editing technology that allows scientists to precisely alter DNA &ndash; may have the potential to cure various genetic disorders. Crispr aims to do so by essentially fixing faulty genes.



While CRSP stock is certainly enticing, its main challenge is profitability (or lack thereof). In the past year since the second quarter, Crispr posted an average loss per share of 81 cents. Now, in Q4 of last year, it posted earnings per share of $1.10, beating the expected loss of 7 cents. That demonstrates that Crispr has potential &ndash; it just needs to demonstrate this more often.



Right now, it&rsquo;s not the most attractively priced security, trading hands at 14.7x trailing-year sales. In contrast, the biotech sector&rsquo;s <a href="https://fullratio.com/ps-ratio-by-industry">average revenue multiple sits at 6.23x</a>. Still, in the past year, CRSP&rsquo;s average price-to-sales ratio stood at 27.09.



After a potentially rough outing in fiscal 2024, the following year could see <a href="https://finance.yahoo.com/quote/crsp/analysis">sales rise to $332.54 million</a>, with a blistering high-side estimate of $3.31 billion.



<h2>Voyager Therapeutics (VYGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Focused on the development of gene therapies for severe neurological diseases, Voyager Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vygr-stock-quote/">VYGR</a>) represents one of the top biotech stocks to consider. Its lead candidate is VY-TAU01, which is an anti-tau antibody program for the treatment of Alzheimer&rsquo;s disease. In its pipeline, it also features a gene therapy that addresses amyotrophic lateral sclerosis or ALS.



As with other biotech stocks, Voyager has trouble with generating consistent profitability. True, in Q4, the company posted EPS of $1.25. This dramatically exceeded the consensus target calling for a loss of 29 cents per share. However, the company has struggled in other quarters to print positive results. That also didn&rsquo;t change with the <a href="https://investorplace.com/earning-results/2024/08/vygr-stock-earnings-voyager-therapeutics-for-q2-of-2024/">latest Q2 results</a>.



At the moment, VYGR stock trades hands at 3.23x sales. While that seems undervalued, it&rsquo;s a deceptive figure since analysts are projecting that by the end of this year, sales may land at $48.51 million. If so, that would imply an 80.6% drop from last year&rsquo;s tally of $250.01 million.



However, because of the demand for treatment solutions for neurological diseases, VYGR stock is worth keeping on your watchlist.



<h2>Sarepta Therapeutics (SRPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/genetics-dna-flgt-1600-300x169.jpg" alt="a visualization of DNA in a vial. TSHA stock"><div>Source: Connect world / Shutterstock.com</div></div>A specialist in the field of precision genetic medicine, Sarepta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/">SRPT</a>) focuses on rare neuromuscular diseases. In particular, its RNA-targeted therapies and gene therapies provide hope for patients suffering from conditions such as Duchenne muscular dystrophy. While SPRT stock has been a strong performer this year, the market fallout has negatively impacted the company&rsquo;s valuation.



Curretnly, SRPT stock trades hands at 9.53x sales. That&rsquo;s a modest discount compared to the prior year&rsquo;s average multiple of 9.57x. Further, it&rsquo;s elevated compared to the industry average. However, it&rsquo;s worth pointing out that in fiscal 2024, analysts <a href="https://finance.yahoo.com/quote/srpt/analysis">project sales to hit $2.02 billion</a>. If so, this figure would represent a 62.6% lift from the prior year&rsquo;s haul of $1.24 billion. In addition, the high-side estimate calls for $2.32 billion.



Assuming a shares outstanding count of 94.52 million, SRPT is currently trading at around 5.73x projected high-side revenue. It&rsquo;s more than possible that Sarepta could hit that target considering that in fiscal 2025, the consensus view for sales calls for $3.27 billion. With so much excitement built into this space, SRPT ranks among the biotech stocks to buy.



<h2>Regenxbio (RGNX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>Another gene-therapy focused enterprise, Regenxbio (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgnx-stock-quote/">RGNX</a>) is a clinical-stage biotech that utilizes a proprietary platform called NAV Technology. This platform enables Regenxbio to develop advanced therapeutic candidates for vexing conditions such as wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. It also features solutions for other conditions such as muscular dystrophy.



Coming upon a familiar theme among biotech stocks, Regenxbio has trouble with consistent profitability. In the past year since Q2, the company incurred a loss per share of $1.32. That said, analysts anticipated a loss of $1.34 during the same period. Therefore, the biotech managed to post a modest &ldquo;earnings&rdquo; surprise of 0.92%.



Right now, RGNX stock trades hands at 6.47x sales. That&rsquo;s roughly in line with the industry average. However, it&rsquo;s noticeably lower than the prior year&rsquo;s average multiple of 7.86x. Analysts see modest growth this year. However, in fiscal 2025, sales could soar to $249.2 million, a far cry from last year&rsquo;s print of $90.24 million.



<h2>Blueprint Medicines (BPMC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/nktx_cancerresearch1600-300x169.png" alt="DNA strand and Cancer Cell Oncology Research Concept 3D rendering. LIXT Stock"><div>Source: CI Photos / Shutterstock.com</div></div>Another specialist in the field of precision medicine, Blueprint Medicines (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpmc-stock-quote/">BPMC</a>) focuses on specific groups of cancers and rare diseases. It&rsquo;s potentially one of the groundbreaking biotech stocks thanks to the underlying targeted approach to cancer treatment. Essentially, Blueprint designs therapeutics based on the specific genetic mutations catalyzing the disease, potentially improving efficacy and reducing complications.



As with other biotech stocks, Blueprint is sporadic in terms of its bottom line. In the past year since Q2, the company posted an average loss per share of 86 cents. In Q1, it managed to deliver EPS of $1.40, far exceeding the expected loss of $1.66. However, investors will eventually want to see more of these positive figures.



Now, BMPC stock is risky, trading hands at 16.06x sales. That&rsquo;s a screaming hot premium. But to be fair, in the prior year, the average multiple stood at 21.41x. The kicker, though, is the fiscal 2024 forecast. Experts believe that revenue could jump to $491.86 million. If so, that would imply a near doubling from last year&rsquo;s print of $249.38 million.



<h2>Precision BioSciences (DTIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/gene-edit-300x169.png" alt="An image of a scientist holding forceps, taking a piece of a DNA helix"><div>Source: Panuwach/Shutterstock</div></div>A biotechnology firm focused on the genome editing, Precision BioSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtil-stock-quote/">DTIL</a>) utilizes a proprietary platform called ARCUS to develop therapies for genetic diseases and cancer. Theoretically, this unique platform enables Precision to design highly specified genetic modifications. This process can potentially lead to more effective and safer therapies.



Unlike many other biotech stocks in its class, Precision has started to generate consistent profits. In the second half of 2023, the company incurred an average loss per share of $3.08. However, in the first half of this year, the average EPS stands at almost $3.19. In the past four quarters, the average EPS is 5 cents, yielding an earnings surprise of 139.8%.



Enticingly, shares trade hands at only 0.51x sales. What&rsquo;s more, in the prior year, the market accepted a multiple of 1.1x. Therefore, DTIL stock potentially has room to run. That&rsquo;s exactly what analysts are anticipating, projecting that fiscal 2024 sales may hit $72.47 million. That&rsquo;s up 48.7% from last year&rsquo;s tally of $48.73 million.



<h2>Allogene Therapeutics (ALLO)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/allogene.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/allogene-300x169.jpg" alt="The logo for Allogene Therapeutics Inc (ALLO) is displayed on a building front."></a>A clinical-stage immuno-oncology firm, Allogene Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allo-stock-quote/">ALLO</a>) develops and commercializes genetically engineered allogeneic T-cell therapies for the treatment of cancer. Specifically, its platform targets pediatric and adult patients suffering from leukemia. According to its website, one of Allogene&rsquo;s core advantages is its scalable and efficient manufacturing process. This attribute enables potentially lifesaving care at reduced cost, holistically easing the burden of treatment.



Allogene isn&rsquo;t a profitable enterprise so it will require significant patience &ndash; more so than many other biotech stocks. In addition, the company doesn&rsquo;t generate much in terms of revenue. Last year, the company posted only $95,000 on the top line. What&rsquo;s worse, by the end of the current year, analysts believe that sales could dip to $50,000.



So, why bother with ALLO stock? Aside from the groundbreaking treatment potential, covering experts believe that by fiscal 2025, revenue could soar to $4.1 million. Further, the high-side estimate calls for $60.97 million.



Interestingly, assuming a shares outstanding count of 208.78 million, ALLO stock is trading at 8.53x projected high-side 2025 revenue. That&rsquo;s not bad considering the therapeutic potential.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor held a LONG position in CRSP.&nbsp;
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/7-biotech-stocks-to-buy-for-their-game-changing-potential/">7 Biotech Stocks to Buy for Their Game-Changing Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Biotech Stocks to Buy for Their Game-Changing Potential

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated pric...

Buy Rating on Precision BioSciences Highlighted by Promising Gene Editing Pipeline and Potential Hepatitis B Cure

The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read… The biotech industry is currently seeing a heightened demand for high-quality healthcare, innovative treatments, and advanced solutions, largely due to an aging population and escalating healthcare requirements. Given its rapid pace of innovation and promising growth potential, investing in select biotech stocks could be wise.
Amid this backdrop, fundamentally robust biotech stocks such as Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>), BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), and Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>) could offer significant return potential owing to their dominance in high-demand areas and transformative treatments.
The biotechnology industry is experiencing rapid growth due to rising demands for personalized medicine, tailored treatments, and the approval of new drugs by the Food and Drug Administration (FDA).
This trend is highlighted in a survey conducted by GlobalData, which reveals that 44% of healthcare industry professionals globally are <a href="https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/">optimistic or extremely optimistic</a> about the recovery of biotech funding in the next twelve months.
Incorporating Generative AI (GenAI) into biotechnology subjects is also revolutionizing the industry by enabling companies to derive valuable consumer insights, craft precise marketing strategies, and redefine healthcare engagements.
According to the McKinsey Global Institute, the integration of GenAI is anticipated to contribute an annual economic value of <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-ai-in-commercial-life-sciences">$60 billion to $110 billion</a> for pharmaceutical and medtech firms.
Furthermore, according to a report by Precedence Research, the U.S. biotechnology market was valued at $246.18 billion in 2023 and is expected to expand at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size,with%20revenue%20share%20in%202023.">a CAGR of 11.6%</a>, reaching approximately $830.31 trillion by 2034.
Considering these factors, let's discuss the fundamentals of three high-potential <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks under $10, starting with #3.
Stock #3: Fulcrum Therapeutics, Inc. (<a href="https://stocknews.com/stock/FULC/">FULC</a>)
FULC is a clinical-stage biopharmaceutical company focused on treating genetically defined rare diseases. Its clinical product candidates, losmapimod and FTX-6058, are developed for facioscapulohumeral muscular dystrophy (FSHD) and sickle cell disease (SCD), respectively.
On May 13, FULC announced its <a href="https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-enters-collaboration-and-license-agreement">collaboration and license agreement</a> with Sanofi (<a href="https://stocknews.com/stock/SNY/">SNY</a>) for the development and commercialization of losmapimod, for the treatment of FSHD. SNY obtains exclusive commercialization rights for losmapimod outside of the United States under the agreement.
With the help of SNY's global reach, it could become easier for FULC to expand its pipeline and grab a stronger market presence in the FSHD treatment zone.
For the fiscal 2024 second quarter that ended on June 30, 2024, FULC's collaboration revenue increased significantly year-over-year to $80 million. The company's <a href="https://www.investopedia.com/terms/i/ifo.asp">income from operations</a> came in at $52.49 million, compared to a loss of $27.29 million in the previous year's quarter.
Also, its net income and net income per share were reported to be $55.41 million and $0.87, compared to a net loss and net loss per share of $23.78 million and $0.38, respectively.
Analysts expect FULC's revenue to increase 707.3% year-over-year to $7.03 million for the fiscal fourth quarter ending December 2024. Meanwhile, the consensus revenue estimate of $86.56 million for the fiscal year ending December 2024 reflects a significant year-over-year rise.
FULC's stock has gained 30.2% over the past three months and 96.4% over the past nine months to close the last trading session at $9.39.
FULC's bright outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
FULC has a B grade for Value and Quality. It is ranked #26 among 341 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/FULC/">Click here</a> to access FULC's ratings for Growth, Stability, Momentum, and Sentiment.
Stock #2: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)
BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics for rare diseases. Its products include ORLADEYO for hereditary angioedema prevention and RAPIVAB for acute uncomplicated influenza treatment in the United States.
On July 9, BCRX announced that its <a href="https://ir.biocryst.com/news-releases/news-release-details/orladeyor-berotralstat-approved-peru">oral, once-daily medication ORLADEYO&#xAE;</a> received approval from the General Directorate of Medicines, Supplies, and Drugs (DIGEMID) in Peru. The approval allows ORLADEYO&#xAE; to be used for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.
Moreover, the approval in Peru adds to BCRX's established presence in the pan-Latin America region, following previous approvals in Chile, Argentina, Brazil, and Mexico. It signifies a significant milestone for BCRX, expanding its market and potentially attracting more customers seeking treatment for HAE.
BCRX's total revenues increased 32.5% year-over-year to $109.33 million for the fiscal 2024 second quarter that ended June 30, 2024.  Its adjusted income from operations also increased to $21.93 million compared to a loss of $7.86 million in the previous year's quarter.
In addition, as of June 30, 2024, BCRX's cash, cash equivalents and investments amounted to $336.34 million while total assets came in at $472.42 million.
BCRX's consensus revenue estimate of $113.89 million for the fiscal third quarter ending September 2024 reflects a year-over-year increase of 31.3%. Also, for the fiscal fourth quarter ending December 2024, BCRX's revenue is expected to increase by 26% from the prior year to $117.67 million.
In addition, BCRX has topped the consensus revenue estimates in all of the trailing four quarters, which is impressive.
Shares of BCRX have surged 31.3% in the past three months and 45.8% in the past nine months to close the last trading session at $8.05.
BCRX's robust outlook is reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.
BCRX has a B grade for Growth, Sentiment, Value, and Quality. It has ranked #17 out of 341 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/BCRX/">Click here</a> to access BCRX's ratings for Stability and Momentum.
Stock #1: Precision BioSciences, Inc. (<a href="https://stocknews.com/stock/DTIL/">DTIL</a>)
DTIL is an innovative gene editing company specializing in developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. The company's focus is on advancing gene edits and transformative treatments within these critical medical fields.
On August 9, DTIL announced <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-investigational-new-drug">U.S. Food and Drug Administration's (FDA) approval</a> for its partner TG Therapeutics, Inc. (<a href="https://stocknews.com/stock/TGTX/">TGTX</a>) to commence Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for its Investigational New Drug (IND) Application for progressive forms of multiple sclerosis (MS).
As the company receives approvals for its drugs in the auto-immune disease treatment market, it ensures a stronger market presence and presents better growth prospects.
On July 1, DTIL announced its addition to the <a href="https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-its-addition-russell-microcapr">Russell Microcap&#xAE; Index</a>, a key benchmark utilized by investment managers and institutional investors for index funds. The inclusion could lead to heightened visibility globally, attracting potential investors and fostering further growth opportunities for the company.
<div class="flex-1 overflow-hidden">
<div class="h-full">
<div class="react-scroll-to-bottom--css-ulgnp-79elbk h-full">
<div class="react-scroll-to-bottom--css-ulgnp-1n7m0yu">
<div class="flex flex-col text-sm md:pb-9">
<article class="w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]" dir="auto" data-testid="conversation-turn-17" data-scroll-anchor="true">
<div class="text-base py-[18px] px-3 md:px-4 m-auto md:px-5">
<div class="mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl">
<div class="group/conversation-turn relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex-col gap-1 md:gap-3">
<div class="flex max-w-full flex-col flex-grow">
<div class="min-h-[20px] text-message flex w-full flex-col items-end gap-2 break-words [.text-message+&amp;]:mt-5 overflow-x-auto whitespace-normal" dir="auto" data-message-author-role="assistant" data-message-id="8fe0c70b-67a1-4de1-a838-d3c1def07b65">
<div class="flex w-full flex-col gap-1 empty:hidden first:pt-[3px]">
<div class="markdown prose w-full break-words dark:prose-invert dark">
For the fiscal 2024 second quarter that ended June 30, DTIL's revenue increased 152.2% year-over-year to $49.90 million. Its operating income amounted to $24.15 million compared to a loss of $3.13 million in the previous year's quarter.
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</article>
</div>
</div>
</div>
</div>
</div>
Additionally, the company's net income and net income per share came out to be $32.75 million and $4.67 compared to a net loss and loss per share of $11.89 million and $3.13, respectively.
Analysts project DTIL to achieve $57.40 million in revenue for the fiscal year ending December 2024, reflecting a 17.8% year-over-year increase. Additionally, the company is expected to report an EPS of $2.10 for the period. Notably, DTIL has exceeded consensus revenue estimates in three of its last four quarters.
DTIL's shares marginally declined intra-day close the last trading session at $9.85.
The stock's positive fundamentals are reflected in its POWR Ratings. DTIL has an overall rating of B, which equates to a Buy in our proprietary rating system.
DTIL has an A grade for Sentiment and a B grade for Value. It is ranked #16 out of 341 stocks within the same industry.
<a href="https://stocknews.com/stock/DTIL/">Click here</a> to access DTIL's ratings for Stability, Quality, Growth, and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt; </a>
&nbsp;

<hr />
BCRX shares were trading at $8.05 per share on Tuesday morning, down $0.18 (-2.19%). Year-to-date, BCRX has gained 34.39%, versus a 18.97% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/bcrx-fulc-dtil-tgtx-sny-3-high-potential-biotech-stocks-under-10/>3 High-Potential Biotech Stocks Under $10</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Potential Biotech Stocks Under $10

The latest announcement is out from Precision BioSciences (DTIL). Precision BioSciences, Inc. recently announced the successful maturity of a $13 m...

Precision BioSciences Secures Funds, Bolsters Oncology Partnership

An announcement from Precision BioSciences ( ($DTIL) ) is now available. Precision BioSciences, a leading gene editing company, has announced adjus...

Precision BioSciences Reshuffles Clinical Leadership Team

ABEV

ABUS

ACIW

AGIO

ALGM

ALLO

ALNY

APLS

APPN

APTV

ATGFF

ATUS

AUPH

AXTA

BALL

BAND

BCRX

BIGC

BIIB

BIPC

BMWYY

BPMC

BRPHF

CAMT

CCRD

CPSH

CRIS

CROX

CRSP

CRTO

CWEN

DHLGY

DINO

DRVN

EVGO

EXLS

FTDR

FULC

GOOS

SRPT

VYGR

Press Releases

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Events

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Precision BioSciences

Precision BioSciences (DTIL) Forecast

Precision BioSciences (NASDAQ:DTIL) Stock, Quote.Headers.trade-ideas